Antibodies | Applications of Bispecific Antibodies in Acute Myeloid Leukemia: From Bone Marrow Immune Microenvironment to Clinical Translation

This study systematically reviews the mechanisms and clinical potential of bispecific antibodies in acute myeloid leukemia, providing direct theoretical support for designing novel immunotherapeutic strategies that target leukemic stem cells (LSCs) and remodel the bone marrow immune microenvironment.

 

Literature Overview

The article titled “Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation,” published in the journal Antibodies, systematically explores the remodeling mechanisms of the bone marrow immune microenvironment in acute myeloid leukemia (AML) and their impact on immunotherapy responses. The article focuses on the application of bispecific antibodies (bsAbs) targeting antigens such as CD33, CD123, and CD70, revealing how dynamic interactions between LSCs and immunosuppressive cells create a “leukemic immune sanctuary.” The study further proposes that redirecting T cells or NK cells via bsAbs can bypass MHC-restricted recognition, enhancing LSC clearance. The article also summarizes current clinical trial data, highlighting challenges such as CRS management and antigen escape, providing a systematic framework for future research.

Background Knowledge

1. The key challenge in AML addressed by this study is that conventional chemotherapy and targeted therapies fail to eradicate LSCs, leading to high relapse rates and poor outcomes, especially in elderly or high-risk patients. Although antibody–drug conjugates such as GO have been used, their efficacy remains limited by antigen heterogeneity and the immunosuppressive bone marrow environment. 2. Current research bottlenecks for CD33 and CD123 as primary targets include their low-level expression on normal hematopoietic stem cells, raising the risk of “on-target, off-tumor” toxicity, while low antigen density and microenvironment-induced T-cell exhaustion limit the durability of bsAb responses. 3. The study’s innovative angle extends AML treatment strategies beyond simply targeting tumor cells to include modulation of the bone marrow immune microenvironment. By enabling bsAbs to simultaneously recognize LSC surface antigens and immune effector cells (e.g., T or NK cells), MHC-independent cytotoxicity can be achieved. This approach is particularly relevant for high-risk AML with TP53 mutations, where conventional therapies are less effective. The article emphasizes that combining bsAbs with background therapies such as HMAs and venetoclax may enhance antigen expression and improve effector cell function, thereby increasing response rates.

 

 

Research Methods and Experiments

The authors employed a systematic literature review approach, integrating recent advances in research on the AML bone marrow microenvironment, immune escape mechanisms, and clinical development of bsAbs. The study focused on analyzing the structure–function relationships of various IgG-like and non-IgG-like bsAbs, including platforms such as BiTE, DART, and TriKE. By summarizing data from multiple phase I/II clinical trials (e.g., APVO436, flotetuzumab, AMG 330), the safety and efficacy of different bsAbs in R/R AML patients were evaluated. Additionally, the study explored the roles of MDSCs, LAMs, and CAR cells in establishing an immunosuppressive microenvironment and proposed combination targeting strategies to enhance bsAb functionality.

Key Conclusions and Perspectives

• CD123-targeting bsAbs (e.g., flotetuzumab) have demonstrated high complete remission rates (26.7%) in TP53-mutated AML, suggesting their potential to overcome resistance associated with adverse molecular features and offering a new therapeutic direction for TP53-mutated patients.
• CRS is the most common toxicity in bsAb therapy, but most cases are grade 1–2 and can be effectively managed with tocilizumab, indicating that clinical management strategies are maturing and supporting broader trial enrollment.
• TriKEs (e.g., GTB-3650), which activate NK cells to kill LSCs, show lower CRS incidence, suggesting they may serve as an important alternative for patients with T-cell exhaustion, particularly those with preserved NK cell function.
• Antigen escape remains a major resistance mechanism; combining CD33 and CD123 targeting or incorporating checkpoint inhibitors (e.g., anti-TIM-3) may enhance durable responses, driving the development of multi-target synergistic strategies.

Research Significance and Prospects

This study provides a systematic blueprint for AML immunotherapy, emphasizing that bsAbs are not only tools for redirecting effector cells but also key agents in reshaping the bone marrow immune ecosystem. From a drug development perspective, optimizing the balance between half-life and tissue penetration will be central to next-generation bsAb design. For clinical monitoring, dynamic assessment of MRD and immune microenvironment markers (e.g., PD-1, IL-6) will help identify responders and guide the timing of combination therapies. In disease modeling, humanized mouse models (e.g., HSC-engrafted NSG) can simulate LSC–niche interactions and validate bsAb efficacy within a physiological microenvironment.

 

 

Conclusion

From bench to bedside, bispecific antibodies represent a significant leap in AML therapy, transitioning from cytotoxic chemotherapy to precise immune intervention. This study not only elucidates how the bone marrow immune microenvironment shelters LSCs but also systematically evaluates the clinical translation potential of various bsAb platforms. In the future, sequential strategies integrating bsAbs with HMAs, venetoclax, or alloSCT may achieve deeper molecular remissions. Particularly in high-risk AML, bsAbs targeting CD123 or CLEC12A may become crucial bridging tools to transplantation. Furthermore, developing NK cell-based TriKEs or tetravalent antibodies will expand the frontiers of immunotherapy. Ultimately, personalized selection of bsAbs should integrate mutation profiles, antigen expression levels, and immune microenvironment status, ushering AML into an era of precision immunotherapy and reshaping long-term survival trajectories for patients.

 

Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, and Massimo Gentile. Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation. Antibodies.